Expand ADMS Menu
ADMS MENU

About ADMS

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication associated with the treatment of Parkinson's disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company's portfolio also includes two approved products with Forest Laboratories Holdings Limited (a subsidiary of Actavis plc), Namzaric(TM) and Namenda XR(R). Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ADMS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 87.7 M 8.77399E+07 1,991 1991 0.0% 1.56223E-05 4,359 4359
UWM ProShares Ultra Russell2000 216.2 M 2.16193E+08 1,991 1991 0.0% 2.46412E-05 11 K 11366
VTWV Vanguard Russell 2000 Value ETF 278.4 M 2.784E+08 1,398 1398 0.01% 0.000120165 34 K 34178
ITOT iShares Core S&P Total U.S. Stock Market ETF 26.3 B 2.63131E+10 3,660 3660 0.0% 0 153 K 152614
IWC iShares Microcap ETF 857.4 M 8.57401E+08 1,384 1384 0.04% 0.0004 304 K 304242
IWM iShares Russell 2000 ETF 45.2 B 4.51845E+10 1,981 1981 0.01% 0.0001 2.8 M 2839960
IWN iShares Russell 2000 Value ETF 9.4 B 9.41866E+09 1,388 1388 0.01% 0.0001 1.3 M 1288150
IWV iShares Russell 3000 ETF 10.5 B 1.05227E+10 2,878 2878 0.0% 0 36 K 36291
IEIH iShares Evolved U.S. Innovative Healthcare ETF 5.7 M 5724620 232 232 0.01% 0.0001 516 516